WO2002007740A3 - Schlangentoxin und dessen verwendung als arzneimittel - Google Patents

Schlangentoxin und dessen verwendung als arzneimittel Download PDF

Info

Publication number
WO2002007740A3
WO2002007740A3 PCT/EP2001/007977 EP0107977W WO0207740A3 WO 2002007740 A3 WO2002007740 A3 WO 2002007740A3 EP 0107977 W EP0107977 W EP 0107977W WO 0207740 A3 WO0207740 A3 WO 0207740A3
Authority
WO
WIPO (PCT)
Prior art keywords
pharmaceutical
peptide
relates
snake toxin
alleles
Prior art date
Application number
PCT/EP2001/007977
Other languages
English (en)
French (fr)
Other versions
WO2002007740A2 (de
Inventor
Christoph Methfessel
Viktor Tsetlin
Yuri Utkin
Original Assignee
Bayer Ag
Christoph Methfessel
Viktor Tsetlin
Yuri Utkin
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ag, Christoph Methfessel, Viktor Tsetlin, Yuri Utkin filed Critical Bayer Ag
Priority to AU2001276394A priority Critical patent/AU2001276394A1/en
Publication of WO2002007740A2 publication Critical patent/WO2002007740A2/de
Publication of WO2002007740A3 publication Critical patent/WO2002007740A3/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Die vorliegende Erfindung betrifft ein Peptid mit der Aminosäuresequenz (I) oder davon abgeleitete Allele beziehungsweise Peptide, die wesentliche Teile des Peptids (I) enthalten, ein Verfahren zu dessen Herstellung und dessen Verwendung zur Herstellung eines Arzneimittels zur Behandlung von Krankheiten, die durch Inhibierung des α7-nACh-Rezeptors therapiert werden können, wobei es sich insbesondere um die Behandlung von Krebs wie das kleinzellige Lungenkarzinom handelt.
PCT/EP2001/007977 2000-07-24 2001-07-11 Schlangentoxin und dessen verwendung als arzneimittel WO2002007740A2 (de)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2001276394A AU2001276394A1 (en) 2000-07-24 2001-07-11 Snake toxin and use thereof as a pharmaceutical

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10035854A DE10035854A1 (de) 2000-07-24 2000-07-24 Schlangentoxin und dessen Verwendung als Arzneimittel
DE10035854.3 2000-07-24

Publications (2)

Publication Number Publication Date
WO2002007740A2 WO2002007740A2 (de) 2002-01-31
WO2002007740A3 true WO2002007740A3 (de) 2002-06-20

Family

ID=7649937

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2001/007977 WO2002007740A2 (de) 2000-07-24 2001-07-11 Schlangentoxin und dessen verwendung als arzneimittel

Country Status (4)

Country Link
US (1) US20020150975A1 (de)
AU (1) AU2001276394A1 (de)
DE (1) DE10035854A1 (de)
WO (1) WO2002007740A2 (de)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7259237B1 (en) 2006-12-29 2007-08-21 Miller Kent D Pan-antiviral peptides
US9220743B2 (en) 2010-01-22 2015-12-29 Nuovo Biologics, Llc Pan-antiviral peptides for protein kinase inhibition
CN103849540B (zh) * 2014-03-13 2017-08-22 陈海峰 一种蛇蝎益气养生酒及其制备方法
CN109651496A (zh) * 2018-11-20 2019-04-19 南京昂峰医药科技有限公司 一种蛇毒蛋白储备液、其组合物以及稳定蛇毒蛋白的方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5232911A (en) * 1990-01-03 1993-08-03 Ventech Research Inc. Mixture of a non-covalent heterodimer complex and a basic amphiphatic peptide as cytotoxic agent
US5565431A (en) * 1994-06-20 1996-10-15 Lipps; Binie V. Cancer cell inhibitors and method
ES2112803A1 (es) * 1996-09-23 1998-04-01 Gil Salvador Contri Nuevo procedimiento para la obtencion de un producto organico destinado al tratamiento y curacion de melanomas, carcinomas y otras enfermedades celulares o no celulares.

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5232911A (en) * 1990-01-03 1993-08-03 Ventech Research Inc. Mixture of a non-covalent heterodimer complex and a basic amphiphatic peptide as cytotoxic agent
US5565431A (en) * 1994-06-20 1996-10-15 Lipps; Binie V. Cancer cell inhibitors and method
ES2112803A1 (es) * 1996-09-23 1998-04-01 Gil Salvador Contri Nuevo procedimiento para la obtencion de un producto organico destinado al tratamiento y curacion de melanomas, carcinomas y otras enfermedades celulares o no celulares.

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
JOUBERT FJ & TALJAARD N: "The Amino Acid Sequences of Two Melanoleuca-Type Toxins", HOPPE-SEYLER'S ZEITSCHRIFT FÜR PHYSIOLOGISCHE CHEMIE, vol. 361, March 1980 (1980-03-01), pages 425 - 436, XP001053752 *
UTKIN YN ET AL.: "First tryptophan-containing weak neurotoxin from cobra venom", TOXICON, vol. 39, no. 7, July 2001 (2001-07-01), pages 921 - 927, XP001053743 *

Also Published As

Publication number Publication date
WO2002007740A2 (de) 2002-01-31
AU2001276394A1 (en) 2002-02-05
DE10035854A1 (de) 2002-02-07
US20020150975A1 (en) 2002-10-17

Similar Documents

Publication Publication Date Title
WO2003070760A3 (en) Anti-amyloid beta antibodies and their use
EP1308459A3 (de) Vollständige cDNA-Sequenzen
EP1440981A3 (de) Vollständige humane cDNS
WO2006087637A3 (en) Anti her2/neu antibody
SI0917571T1 (en) Agouti-related gene
WO2001055178A3 (en) Liv-1 related protein, polynucleotides encoding the same and use thereof for treatment of cancer
WO2002061076A1 (en) Adiponectin-associated protein
WO2002090502A3 (en) Highly conserved proteins from gram-positive bacteria
WO2008047370A3 (en) Compositions and methods for inducing angiogenesis
WO2003022868A3 (en) Metal binding proteins and associated methods
WO2002007740A3 (de) Schlangentoxin und dessen verwendung als arzneimittel
EP1422243A4 (de) Humanisierter antikörper gegen fibroblast growth factor 8 und fragment des antikörpers
WO2003048317A3 (en) Antibodies to magmas and uses thereof
UA83989C2 (ru) Выделенный пептид, который стимулирует противоопухолевый иммунный ответ, фармацевтическая композиция на его основе и ее применение
WO2004000289A3 (de) Zubereitungen zur intranasalen applikation ausgewählter, von aminosäuren abgeleiteter grp-antagonisten
WO2005116658A3 (en) Method for determining a tissue degradation process by detection of comp neoepitopes
WO2002083727A3 (de) Nukleinsäuresequenzen von hyperplasien und tumoren der schilddrüse
WO2005105838A3 (en) Ion channel
WO2004111200A3 (en) Rtvp-glipr-like compositions and methods for the detection, treatment and prevention of prostate cancer
AU2003202489A1 (en) Screening method
WO2003070770A3 (en) Engineered human kunitz-type protease inhibitor
WO2003089461A3 (en) Purified dutpase from helicobacter pylori
IL142664A0 (en) Prv-1 gene, processes for detecting the prv-1 polypeptide and pharmaceutical compositions containing the same
WO2002044379A3 (en) Transforming growth factor-beta-related molecules and uses thereof
WO2003033652A3 (en) TUMOR ENDOTHELIAL MARKER 5α MOLECULES AND USES THEREOF

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP